Alerts

Important human microbial ecological system modulator - FMT or one of the best clinical applications of epigenetics in gastroenterology

Diana ZandereDuring Targeting Microbiota World Congress 2016, Dr. Diana Zandere from the University of Riga, Latvia will talk about the important human microbial ecological system modulator - FMT (fecal microorganism transplantation) or one of the best clinical applications of epigenetics in gastroenterology.

At the end of Dr Zandere's presentation, the following questions will be answered:

  1. Have there been FMT donor selection with appropriate donor-recipient sex matching (i.e.young female to female, young male to male and so on) in order to enhance FMT colonization success?
  2. Should donors or recipients adhere for a certain period of time to agluten diet for better therapeutic gain (think zonulin-occludin systems and/or N-(phosphonomethyl) glycine?
  3. Is nutritional background as an important GI microbiome modulator & epigenetic modulator being investigated enough in connection to FMT and/or probiotic or sinbiotic "loading"? Polypharmacy + probiotics without true enteric coating + frozen unmatched FMT donor material + long term nutritional management absent +xenoestrogens+ recipient with organ deficiency=...?

 

If you are interested to know more about human microbial ecological system, you can join the participants of Targeting Microbiota World Congress by registering here.

www.microbiota-site.com

Marvin Edeas, Chairman of ISM

Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection

JJ Quereda Microbiota Paris2016The scientific committee of the International Society of Microbiota invited Dr Juan José Quereda from the Institut Pasteur to give a talk about Bacteriocin from epidemic Listeria strains alters the host intestinal microbiota to favor infection.

During his talk, Dr Quereda will answer the following questions:

1) Does Listeria monocytogenes produce any bacteriocin and where is it produced?
2) Does this bacteriocin alter the host intestinal microbiota?
3) Does this bacteriocin impact the infectious potential of the producing L. monocytogenes strains?

If you are interested to know more about this strategic topic, you can register for the 4th World Congress on Targeting Microbiota by clicking here.

Marvin Edeas - Chairman of ISM

The International Society of Microbiota
www.microbiota-site.com

 

Bacteriophages for improving human health: from food additives to dietary supplements

A Sukalvelidze Microbiota Paris2016

The scientific committee of the International Society of Microbiota is honoured to welcome Dr. Alexander Sulakvelidze, Editor-in-chief of Bacteriophage for the 4th edition of Targeting Microbiota World Congress.

During the congress, Dr. Sulakvelidze will talk about bacteriophages for improving human health: from food additives to dietary supplements. According to Dr. Sulakvelidze, the emergence of drug-resistant bacteria has rekindled interest in potential utility of lytic bacteriophages for managing bacterial infections. While most public attention has focused on the use of phages for treating human infections, there are currently no FDA-approved phage products available for human therapeutic applications. It is anticipated that such products will be gradually approved and marketed over the next several years.  Meanwhile, lytic bacteriophages are already improving our health by enhancing our food safety; e.g., several FDA-approved phage-based products are currently on the market for “phage biocontrol” applications. Moreover, application of bacteriophages as dietary supplements / probiotics is also gaining an increased attention, as phages are increasingly being considered for targeted fine-tuning of the human microbiota for health benefits. 

The presentation will give the audience a current perspective about the history of bacteriophage therapy research and the crucial regulatory and human safety issues concerning the use of bacteriophages in various applications ranging from food safety (“phage biocontrol”) to dietary supplements / probiotics.

For more information please visit: www.microbiota-site.com

 

Role of the microbiome in inflammatory bowel diseases: using multi-omics datase

Knut Rudi Microbiota

The microbial ecosystem residing in the human gastrointestinal tract plays an intimate role in the development and well-being of their human host. The gut commensal microbes reside in synergy with the host, undertaking wide range of functions that benefits themselves and their host. These host-associated microbial communities that share different functional genes between distinct bacterial species are increasingly associated with horizontal gene transfer (HGT).

During Targeting Microbiota World Congress, Dr Knut Rudi from the Norwegian University of Life Sciences will discuss the current status and future developments in their knowledge about the infant gut microbiota mobilome will be discussed.

www.microbiota-site.com

 

Marvin Edeas from Institut Cochin, INSERM U1016 will present the challenge to find strategies to modulate the quality and diversity of microbiota

Microbiota marvin edeasOur aim is to highlight the subtle relationship that exists between microbiota and mitochondria. Microbiota targets mitochondria by modulating the Reactive Oxygen Species (ROS) production and the mitochondrial activity through interactions with toxins, proteins or other metabolites released by gut microbiota. The intriguing relationship that exists between mitochondria and microbiota is strengthened by the probable prokaryotic origin of mitochondria. Emerging data implicates a role for ROS, nitric oxide, Short Chain Fatty Acids and hydrogen sulfide in the cross-talk between microbiota – mitochondria and REDOX signaling. Several studies have shown that microbiota act and modulate mitochondrial activity, and use it as a relay to strengthen host-microbiotal interaction. This modulation depends on the gut bacterial strain quality and diversity to increase its pathogenic versus beneficial effects. Furthermore, based on conclusions from new studies, it is possible that microbiota can directly interact with the host cell gene expression by favoring bacterial and mitochondrial DNA insertion in the nuclear genome. The emerging knowledge of mitochondria-microbiota interaction may be of great importance to better understand the mechanism of mitochondrial and metabolic diseases, and the syndromes associated with change in quality and quantity of microbiotal species.  We suggest that microbiota via mitochondrial modulation influence cell homeostasis and metabolism. The challenge will be to find strategies to modulate the quality and diversity of microbiota rather than acting on microbiota metabolites and microbiota related factors. The medicine of tomorrow will be completely personalized. Firstly there will be a test to show the quality, quantity and diversity of microbiota, and secondly a preventive or therapeutic strategy will be administrated (probiotics, diet, prodrug or fecal transplantation). The era of digital medicine is here.

References :
Weissig, V. and Edeas, M., Mitochondrial medicine Vol. I Probing mitochondrial function. Preface. Methods Mol Biol. 2015, 1264
Weissig, V. and Edeas, M., Mitochondrial medicine. Vol. II Manipulating mitochondrial function. Preface. Methods Mol Biol. 2015, 1265

Dr Sean Kennedy, Institut Pasteur, Department of Genome & Genetics will highlight microbiota analysis and bioinformatics

Sean Kennedy2

Dr Sean Kennedy will chair the session about microbiota analysis and bioinformatics.

The scientific committee of ISM believes that bio-informaticians will play the most strategic role to interpret the microbiome and microbiota analysis.

Read more...

Dr. Jasper will hightlight the age-related immune senescence and microbiota dysbiosis

JasperDr. Henri Jasper, Professor and CSO of the Buck Institute for Research on Aging in Novato, Canada, will give a presentation about Age-related immune senescence and microbiota dysbiosis: lessons from the fly, on the 4th World Congress on Targeting Microbiota.

Dr. Jasper’s lab studies the effects of aging on the intestinal microbiota, using Drosophila as a genetically accessible model system. Recent studies have uncovered a critical role for immune deregulation in the development of microbiota dysbiosis in aging animals. The work established that the intestinal epithelium of aging flies develops an inflammatory condition that is characterized by hyper activation of the Relish-NFkB signaling pathway, and results in expansion of the commensal microbiota, a secondary inflammatory response, and over-activation of intestinal stem cell proliferation. By preventing NFkB deregulation, the authors are able to delay these phenotypes and extend lifespan. Current work focuses on age-related changes in microbiota composition and compartmentalization, and new findings will be presented at the conference.

Find more information about the congress here: http://www.microbiota-site.com/
 

Dr. Jasper’s lab studies the effects of aging on the intestinal microbiota, using Drosophila as a genetically accessible model system. Recent studies have uncovered a critical role for immune deregulation in the development of microbiota dysbiosis in aging animals. The work established that the intestinal epithelium of aging flies develops an inflammatory condition that is characterized by hyper activation of the Relish-NFkB signaling pathway, and results in expansion of the commensal microbiota, a secondary inflammatory response, and over-activation of intestinal stem cell proliferation. By preventing NFkB deregulation, the authors are able to delay these phenotypes and extend lifespan. Current work focuses on age-related changes in microbiota composition and compartmentalization, and new findings will be presented at the conference.

The Challenges to control the diversity and variability of microbiota

challenges to control diversity variability microbiota

During Targeting Microbiota 2016, the scientific committee will allocate time to discuss the challenges to control the diversity and variability of microbiota.

Among the challenges which will be discussed:

  • Phage therapy
  • Diet, probiotics and prebiotics
  • CRISPR/Cas system
  • Quorum sensing
  • Fecal Microbiota Transplantation: Clinical & Practical Issues

A special session will be specifically dedicated to the fecal microbiota transplantation. For more information, please click here.

If you are interested to submit your abstracts related to these challenges, please click here.

For more information about Targeting Microbiota 2016: www.microbiota-site.com

 

A session is dedicated to the Microbiota analysis 2016: The challenge of big data interpretation

microbiota sequencing

The Scientific Committee decided to organize a special session about Microbiota analysis 2016: The challenge of big data interpretation.

Read more...

Skin microbiota: Towards a new era in dermocosmetics/ Dermatology

skin microbiota dermatology marvin edeasThis review was based on symposium on skin microbiota which was organized by the International Society of Microbiota on June 17, 2015, Paris, France. Marvin Edeas, Chairman of the Scientific Committee of ISM stated: "This review shortly characterises skin microbiota and their functions. The impact of external factors such as xenobiotics, traumatization, UVB light, cosmetic products and antiseptics are discussed. Strategies to target axillary microbiota to prevent body odour, as well as potential targets to manipulate microbiota in cosmetics and athopic dermatitis are outlined with examples. In future we may expect that knowledge of skin microbionome will allow development of wide range of cosmetical products and stratify patient and people with high predispostion to disease subsets, predict the best treatment or preventiv modality and outcome and introduce new treatment strategies by targetely manipulation of microbial communities."

To access to this review, please contact ISM.

Targeting Microbiota Abstract Submission

Deadline for Short Oral Presentation Abstract Submission:
September 16, 2024

Deadline for Poster Presentation Abstract Submission:
September 19, 2024


Submission Guidelines:

  1. Submit abstracts to the Scientific Committee.
  2. Use the online form for submissions. Abstracts not using this form will not be considered.
  3. One abstract per registered person.
  4. For oral submissions: prioritize in-person presentations. Online presentations require prior approval.
  5. Online poster submissions are accepted.
  6. No changes after the submission deadline.
  7. Abstracts cannot be modified post-acceptance.

Abstract Format:

  1. Title: Max 20 words.
  2. Text: Max 200 words, divided into Introduction, Materials & Methods, Conclusion.
  3. Define unusual abbreviations on first use.
  4. Relate to conference tracks or sessions, and specify the topic.
  5. Include references (max 3).
  6. Submit in both Word and PDF formats, prepared in B5 format.

Download abstract format guidelines here in Word or in PDF.

Abstracts not following the formalities will not be considered.

Microbiota Boutons


 Reviewing and Selection Process

  • All submissions reviewed by the Scientific Committee.
  • Selection based on originality, novelty, impact (score 1-10).
  • Scores 9-10: considered for oral presentation.
  • Scores 6-8: accepted for poster presentation.
  • Preference for in-person short oral presentations.
  • E-posters can be accepted.
  • Low-quality or off-topic abstracts may be rejected.

Published Abstracts

Accepted abstracts will be published in the conference abstracts book.


Short Oral Presentations

  • Duration: 8 minutes presentation, 2 minutes Q&A.
  • Slide limit: 8 slides (+1 for title).
  • Cover research aim, methods, results, conclusion.
  • Timing subject to final program adjustments.

A1 Poster size

 Posters Session

  • Format: A1 vertical (84.1cm x 59.4cm).
  • Presented during coffee and lunch breaks.
  • E-posters to be emailed to: microbiota[at]microbiota-ism.com

 

The ISM awarded Pr Iradj Sobhani for his Scientific Contribution during the 3rd World Congress on Targeting Microbiota

sobhani iradj During the 3rd World Congress on Targeting Microbiota held at Pasteur Institute from October 21 to 23, Pr Iradj Sobhani from Hôpital Universitaire Henri Mondor, France gave a strategic presentation about "Cancer & Microbiota: Potential of fecal microbiota for early-stage detection of colorectal cancer".

 

According Pr Sobhani: "Colorectal cancer (CRC) is one of the main major problems in health care. The incidence is growing in western countries and no evident cause is found although germline DNA mutations in less than 5% of patients are identified and environment factors such as food, style of life, medicine, etc... are now suspected to induce majority of cancers. Exhaustive quantitative and qualitative evaluation of all factors from the environment is not possible. The microbiota may be considered as platform offering host and environment interactions for studying CRCs. And growing data show specific changes in microflora (dysbiosis) in colon cancer patients’ stools or adherent to the colonic mucosa. The hypothesis that colon cancer might be a bacteria-related disease is suggested and perspectives discussed."

The Scientific Committee of the International Society of Microbiota was delighted to award Pr Sobhani for this strategic presentation and his scientific contribution during the international congress.

For more information about the congress: www.microbiota-site.com

ISM is pleased to award three scientists for their oral and poster presentations

 

Awards Poster

The Scientific Committee of the International Society of Microbiota awarded three scientists for their presentations during Targeting Microbiota World Congress which was held in Institut Pasteur, Paris:

- Dr Atti-La Dahlgren, Sweden for her short oral presentation about "Anaerobically Cultivated Human Intestinal Microbiota"

- Dr Heenam Stanley Kim, from Korea for his poster about "Subspecies-level dysbiosis of Faecalibacterium prausnitzii in the human gut microbiome underlies atopic dermatitis"

- Dr Erica Castro de Lourdes, Columbia, for her poster about "Selection of lactic acid bacteria for the prevention of dental caries"

If you would like to access to the abstracts of these three presentations, you can order the abstracts book by clicking here.

For more information about Targeting Microbiota 2015: www.microbiota-site.com

 

 

 

Dr Gurumoorthy Krishnamoorthy was awarded by the Scientific Committee of ISM for his Scientific Contribution

Gurumoorthy Krishnamoorthy

It is an honor to announce the award discerned by The Scientific Committee of ISM to Dr Gurumoorthy Krishnamoorthy from Max Planck Institute of Neurobiology, Germany for his scientific contribution about "The gut-brain axis in the CNS autoimmunity", during Targeting Microbiota 2014.

Read more...

Dr Atti-La Dahlgren was awarded for his presentation about Anaerobically cultivated human intestinal microbiota

ADahlgren

Dr. Dahlgren is a Swedish physician specialised in International Public Health and is affiliated to Karolinska Institutet Department of Microbiology, Tumor and Cell biology, in Stockholm Sweden. His current field of research is the clinical application of Anaerobically Cultivated Intestinal Microbiota, especially in Recurrent Clostridium difficile infections, a major public health concern in US, Canada, Europe and other countries. Since 2003 he in an advisor to the Bhutan Health Trust Fund and the Ministry of Health in the Kingdom of Bhutan.

During Targeting Microbiota World Congress 2005, Dr Dahlgren gave a short oral presentation about "anaerobically cultivated human intestinal microbiota". 

For almost 20 years, Dr Dahlgren's team have produced a human intestinal microbiota under strict anaerobic conditions, as an in vitro batch culture. This cultivated microbial ecosystem designated anaerobic cultivated human intestinal microbiota (ACHIM) has been reinoculated every second week during the years into new production batches. The cultivated microbiota has retained a microbial diversity comparable to that of feces from healthy donors, containing the major bacterial phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria, as confirmed by gene sequencing.This batch-cultured microbial ecosystem has been tested for safety and clinical efficacy for many years in more than 400 patients, most of them suffering from recurrent Clostridium difficile-infection (RCDI). [...] 

A.Dahlgren

The scientific committee was honoured to award Dr Dahlgren for this strategic study.

If you would like to access to the complete abstract, and to the complete abstracts book, you can order it by clicking here.

 

Targeting Microbiota Congress Great moments in Picture

Microbiota 2015 World Congress imagesTargeting Microbiota World congress was a exciting moment, where speakers and participants shared scientific knowledge in Microbiota.

You can find here some pictures of this three-days congress.

Read more...

The Scientific Committee published the final agenda of Targeting Microbiota World Congress

Micorbiota CoverThe Scientific Committee of the International Society of Microbiota published the Final agenda of Targeting Microbiota World Congress.

To access to the final program, please follow this link.

For all information about the congress: www.microbiota-site.com

 

 

The Subltle Balance Between Body Fat, Gut Microbiota and the Brain

john olov janssonJohn-Olov Jansson, of the Sahlgrenska Academy at Gothenburg University, Sweden will be discussing the subtle balance between body fat, gut microbiota and the brain at the 3rd World Congress on Targeting Microbiota, being held between the 21st and 23rd October at the Institut Pasteur, Paris.

The gut microbiota is a complex community including the life forms bacteria and archaea, but dominated by bacteria mainly from the phyla Firmicutes and Bacteroidetes. The effect of gut microbiota on host physiology is not limited to the gastrointestinal tract. Emerging evidence suggest that gut microbiota could influence the central nervous system (CNS). New insight suggests that gut microbiota are an integral component regulation of  energy balance, and that it can be regarded as an organ   that contributes to efficient energy metabolism. The germ free mouse, that completely lacks gut microbiota, is a common model to study the interplay between gut microbiota and metabolism. Total lack of microbiota is a non-physiological condition, and it is nonspecific in its nature. However, it is has proven to be a good model for understanding the most constitutive functions of gut microbiota. In addition, data from alternative models such as probiotic- or antibiotic treatment could be problematic to interpret due to the immense complexity of gut microbiota, as well as our so far unsatisfactory knowledge of its constituents and their interrelations. Data from germfree mice are in line with interactions between  gut microbiota and  neuropeptides such as glucagon-like peptide (GLP-1) and brain derived growth factor (BDNF) in  parts of the brain regulating body fat mass. Further studies are needed to evaluate the biological significance of these findings.

Dr Jansson will present more details and strategies during IMS' Pasteur meeting.

For more information, please visit www.microbiota-site.com/

 

To Swab or Not to Swab? Rectal Swabs for Intestinal Microbiota Analysis

AnatEckMs Anat Eck of the VU Medical Center in the Netherlands will be discussing Rectal Swabs for Intestinal Microbiota at the 3rd World Congress on Targeting Microbiota, being held between the 21st and 23rd October at the Institut Pasteur, Paris.

The composition of the gut microbiota is associated with various disease states, most notably inflammatory bowel disease, obesity and malnutrition. This underlines that analysis of intestinal microbiota is potentially an interesting target for clinical diagnostics. However, since sampling method, storage and processing of samples impact microbiota analysis, it is important to define standards for reproducible and accurate sampling of gut microbiota that can be implemented in clinical routine. 

Ms Eck will present more details and strategies during IMS' Pasteur meeting.

For more information, please visit www.microbiota-site.com/

Who will attend Targeting Microbiota World Congress 2015 from Industries & Academics?

Targeting Microbiota 2015 will gather academics and industrial leaders in the field of microbiota research.

Paris

Among the participants:

Libragen, Genoscreen, Vaiomer, MO BIO, Biocodex, Synthetic Biologics, L'Oréal, Cosmetic Active International, Merial, Laboratoires Clarins, Provital, Evonik Nutrition, AF Consulting, Genetic-Analysis, IPSEN Pharma, Lallemand Health Solutions, Qiagen, Morinaga Milk Industry, Cosmetique Active International, Merial, Laboratoires Clarins Lonza, Dr Pierre Ricaud-Groupe Rocher, BASF Personal Care & Nutrition Provital, L'Oréal Innovation & Research, BASF Beauty Care Solutions Probionov, Merck Kgaa, Pierre Fabre Dermo-Cosmétique, Nutriset Bondonno Natural Health, Bioaster, Nestle Institute of Health Sciences Roquette Freres, Procter & Gamble,Abbio Alma Bio Therapeutics, Rebiotix, Biofortis Seventure Partners, Capsugel

Paris Descartes Unviersity, University of Toyama, University Hospital of Liège, Utah State University, Dept of Thoracic Medicine, Haukeland, University Hospital, CHU de Nice, University of Gothenburg, University of Coimbra, Istituto Italiano Di Tecnologia, Fundación Rioja Salud, Karolinska Institutet, Karolinska Institutet, University Of São Paulo, Paris 13 University, Pontificia Universidad Catolica de Chile, University of Pavia, University of Manchester, The Center for Restorative Medicine, APC Microbiome Institute, University College Cork, Labmet - Ghent University, Department of Public Health and Infectious Diseases, ‘Sapienza’ University of Rome Fondazione Centro San Raffaele, National Institutes of Health/NCI, INSERM, Université d'Auvergne University of Helsinki, CNRS, University of Leipzig, University of Southern Denmark, Shumway Capital Barretos Cancer Hospital - Pio XII Foundation, Hong Kong Baptist University, ACT Health/Australian National University Fondazione IRCCS Istituto Nazionale Dei Tumori, Korea University, University of Turku, University of Zagreb Vanderbilt University, Case Western Reserve University, Chungnam National University, Umeå University Newcastle University, University of British Columbia, Clemson University, Centre for Obesity Research and Innovation, St. Olavs Hospital, INRA / MICALIS University of Frankfurt/Main, University of Sydney, Alimentary Pharmabiotic Centre, University College Cork, UC Davis Texas A&M University, Clinique de Pédiatrie du Saguenay, University of Western Australia,University of Oslo, University of California Davis Sri Ramachandra University, Medical University of Warsaw, Pisa University, Norwegian Veterinary Institute, University of Nebraska-Lincoln, University of Michigan, Hospital Sant Joan De Déu, Vilnius University Hospital Ewha Womans University, Tohoku University, Tehran University of Medical Sciences, Istituto Auxologico Italiano School of Health Sciences Paulo Prata, City of Hope, Korea Research Institute of Bioscience and Biotechnology University Medical Center Hamburg Eppendorf, University of Calgary, Marmara University CSM, King's College London, University of Stavanger, University College Cork Kasetsart University, University of Tartu, Faculté Médecine Marseille, CIDAM, Imgge University of Belgrade, Riga Stradins University...

If you would like to register and join all these leaders in microbiota field: www.microbiota-site.com

 

 

The Interactions Between the Host, the Vaginal Microbiota and Sexually Transmitted Infections: A hot topic of Targeting Microbiota 2015

ravelPr Jacques Ravel will be present at the 3rd World Congress on targeting Microbiota and talk about "The interactions between the host, the vaginal microbiota and sexually transmitted infections"
Pr Ravel is the Associate Director for Genomics at the Institute for Genome Sciences (IGS) and a Professor of Microbiology and Immunology at the University of Maryland School of Medicine in Baltimore, Maryland.


Pr. Ravel’s research program focuses on applying modern genomics technologies and ecological principles to characterize the role and dynamics of the microbial communities inhabiting the human body in health and disease and better define the interactions between the host, the microbes and the environment that drive these ecological systems. Specifically, he is interested in deciphering the role of the vaginal microbiome in women's health using clinical genomics and systems biology approaches, in order to develop improved strategy to manage gynecological and obstetrics conditions. He is the co-Directors of the NIH funded Collaborative Research Center on Sexually Transmitted Diseases entitled Ecopathogenomics of Sexually Transmitted Diseases (EPSTI – epsti.org) which aims at applying systems biology approaches to examine the triangular relationship between human genetic variation, sexually transmitted infections and co-infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae, and the function of the vaginal microbiome.

He is a fellow of the American Academy of Microbiology. Dr. Ravel is the Editor in Chief of the journal Microbiome and an Associated Editor for the journal mBio.

If you would like to know more about Pr Jacques Ravel's study results, don't hesitate and come along to the conference.

For more information: www.microbiota-site.com

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next